dc.contributor.author |
Chandrasena, T.G.A.N. |
en_US |
dc.contributor.author |
Premaratna, R. |
en_US |
dc.contributor.author |
Samarasekera, D.S. |
en_US |
dc.contributor.author |
de Silva, N.R. |
en_US |
dc.date.accessioned |
2016-11-25T09:14:51Z |
en_US |
dc.date.available |
2016-11-25T09:14:51Z |
en_US |
dc.date.issued |
2016 |
en_US |
dc.identifier.citation |
Transactions of the Royal Society of Tropical Medicine and Hygiene. 2016;110(10):620-622 |
en_US |
dc.identifier.issn |
0035-9203 (Print) |
en_US |
dc.identifier.issn |
1878-3503 (Electronic) |
en_US |
dc.identifier.issn |
0035-9203 (Linking) |
en_US |
dc.identifier.uri |
http://repository.kln.ac.lk/handle/123456789/15251 |
en_US |
dc.description |
Indexed in MEDLINE |
en_US |
dc.description.abstract |
BACKGROUND: Sri Lanka was recently declared by WHO to have eliminated lymphatic filariasis as a public health problem, after conclusion of annual mass drug administration. Our aim was to assess the lymphatic filariasis situation, following mass drug administration. METHODS: Surveillance was done in two districts of the Western Province in two consecutive phases (2009-2010 and 2013-2015), by examining 2461 thick night blood smears and performing 250 dipstick tests on children for antibodies to Brugia malayi. RESULTS AND CONCLUSIONS: Decline in bancroftian microfilaraemia (microfilaria rate 0.32% to zero) supports elimination, but re-emergence of brugian filariasisis (antibody rate, 1.6%; one microfilaria positive) is a cause for concern. |
en_US |
dc.language.iso |
en_US |
en_US |
dc.publisher |
Oxford University Press |
en_US |
dc.subject |
Elephantiasis, Filarial |
en_US |
dc.subject.mesh |
Elephantiasis, Filarial-drug therapy |
en_US |
dc.subject.mesh |
Elephantiasis, Filarial-epidemiology |
en_US |
dc.subject.mesh |
Elephantiasis, Filarial-prevention & control |
en_US |
dc.subject.mesh |
Filaricides |
en |
dc.subject.mesh |
Filariasis |
en |
dc.title |
Surveillance for transmission of lymphatic filariasis in Colombo and Gampaha districts of Sri Lanka following mass drug administration |
en_US |
dc.type |
Article |
en_US |